|
|
 |
|
Viewing report
|
|
|
|
The Europe Pharmaceuticals Sectors : A Company and Industry Analysis (July 2005)
Mergent, July 2005, Pages: 32
This report examines the pharmaceuticals sectors in Europe, focusing on the markets in Belgium, France, Germany, Spain, Switzerland and the United Kingdom
Current Environment - Key Points
- The average annual growth rate of Europe's pharmaceutical industry nearly doubled in 2004, from 8% to 15%, with the inclusion of ten new European Union (EU) members
- Most leading European pharmaceutical companies performed exceptionally well in the first quarter of 2005 with good growth in sales and profits
Sanofi-Aventis SA (EURONEXT: SAN), Celesio AG (FSE: CLS), Novartis AG (SWX: NOVN), Roche AG (SWX: RO) and GlaxoSmithKline Plc (LSE: GSK), each reported sales revenue of more than -4 billion
- Drug makers in Europe continued to target Asia as a preferred investment destination
Swiss pharmaceutical giant, Novartis AG spent -148.6 million (US$180 million) to construct a production facility in Singapore, to further strengthen its presence
- In 2004, sales of pharmaceutical products in Europe grew by nearly 18% to achieve a total of -126.3 billion (US$153 billion)
- In the past six months alone, German healthcare company, Stada Arzneimittel AG (FSE: SAZN) bought pharmaceutical companies in Russia and Portugal as well as more than half of the shares of a Chinese pharmaceutical company
Industry Profile - Key Points
- The EU holds 28% of total global pharmaceutical sales and is the second largest pharmaceutical industry in the world
- The UK is one of the few EU countries with a positive trade surplus each year
According to the Association of British Pharmaceutical Industry (ABPI), the UK pharmaceutical's trade surplus in 2004 amounted to -3.4 billion (US$6.2 billion)
- In Germany, rising expenditures and a new reference pricing system is adversely affecting the competitiveness and innovation of the industry
- In the past five years, the annual growth rate of Europe's pharmaceutical research and development (R&D) expenditure has gone down from double-digit growth to single-digit growth
- It is estimated that pharmaceutical research expenditure in 2004 rose by 4.9% from 2003 to reach -21.5 billion (US$26 billion)
Market Trends and Outlook - Key Points
- The take-up of generic drugs in Europe is rising, following a change in drugs use driven by lower costs and the promotion of generic drugs by European governments
- The European generic drugs sector was worth approximately -7 billion (US$8.47 billion) in 2003 and is expected to go up to -15 billion (US$18.2 billion) by 2010
- Research on nanotechnology has been heavily emphasized in the healthcare and pharmaceutical industry over the past two years
For 2002 to 2006, the European Commission has allocated -1.3 billion (US$1.57 billion) in funding for nanotechnology research
- Healthcare costs are expected rise significantly and further burden hard-pressed European governments as the population in Europe continues to age rapidly
However, drug makers should benefit as this means that demand for drugs will rise
- The profitability of the European industry is at risk as a result of falling investment in drug R&D
Apart from a proposed increase in R&D funding, European regulators are considering taking away drug price control regulations
Customers who bought this item also bought
Emerging Generic Drug Markets in Europe
The Europe Pharmaceuticals Sectors : A Company and Industry Analysis (July 2007)
Generic and Innovative Drugs Markets in Central and Eastern Europe 2009
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
European Generic Drug Market Potential
Europe Pharmaceuticals Sectors : A Company and Industry Analysis (September 2008)
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
The Outlook for Pharmaceuticals in Northern Europe to 2013
The Outlook for Pharmaceuticals in Western Europe
The Pharmaceutical Market: Canada
Europe Pharmaceuticals Sectors : A Company and Industry Analysis (January 2008)
SPECIAL REPORT: Blockbusters Then and Now - Trends for Billion-Dollar Drugs
|
|
|
|
